NEW YORK – For the past month, engineering biology firm Sherlock Biosciences has been developing and testing a series of assays for SARS-CoV-2, the pathogen that causes coronavirus disease 2019 (COVID-19). Now, the company believes it is almost ready to release what will likely be the first CRISPR-based diagnostic test for the virus, and is in talks with a variety of possible partners in the US and China to deploy it at a large scale.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.